371 related articles for article (PubMed ID: 27295533)
21. Clinical assessment of the GNAS mutation status in patients with intraductal papillary mucinous neoplasm of the pancreas.
Ohtsuka T; Tomosugi T; Kimura R; Nakamura S; Miyasaka Y; Nakata K; Mori Y; Morita M; Torata N; Shindo K; Ohuchida K; Nakamura M
Surg Today; 2019 Nov; 49(11):887-893. PubMed ID: 30879148
[TBL] [Abstract][Full Text] [Related]
22. Molecular Diagnostics in the Evaluation of Pancreatic Cysts.
Theisen BK; Wald AI; Singhi AD
Surg Pathol Clin; 2016 Sep; 9(3):441-56. PubMed ID: 27523971
[TBL] [Abstract][Full Text] [Related]
23. Pancreatobiliary-type intraductal papillary mucinous neoplasm of the pancreas may have 2 subtypes with distinct clinicopathologic and genetic features.
Shimizu T; Akita M; Sofue K; Toyama H; Itoh T; Fukumoto T; Zen Y
Hum Pathol; 2019 Sep; 91():26-35. PubMed ID: 31175918
[TBL] [Abstract][Full Text] [Related]
24. Lessons from McCune-Albright syndrome-associated intraductal papillary mucinous neoplasms: : GNAS-activating mutations in pancreatic carcinogenesis.
Parvanescu A; Cros J; Ronot M; Hentic O; Grybek V; Couvelard A; Levy P; Chanson P; Ruszniewski P; Sauvanet A; Gaujoux S
JAMA Surg; 2014 Aug; 149(8):858-62. PubMed ID: 24898823
[TBL] [Abstract][Full Text] [Related]
25. Molecular Evidence for Monoclonal Skip Progression in Main Duct Intraductal Papillary Mucinous Neoplasms of the Pancreas.
Date K; Ohtsuka T; Fujimoto T; Tamura K; Kimura H; Matsunaga T; Mochidome N; Miyazaki T; Mori Y; Oda Y; Nakamura M; Tanaka M
Ann Surg; 2017 May; 265(5):969-977. PubMed ID: 28398963
[TBL] [Abstract][Full Text] [Related]
26. Loss of Activin Receptor Type 1B Accelerates Development of Intraductal Papillary Mucinous Neoplasms in Mice With Activated KRAS.
Qiu W; Tang SM; Lee S; Turk AT; Sireci AN; Qiu A; Rose C; Xie C; Kitajewski J; Wen HJ; Crawford HC; Sims PA; Hruban RH; Remotti HE; Su GH
Gastroenterology; 2016 Jan; 150(1):218-228.e12. PubMed ID: 26408346
[TBL] [Abstract][Full Text] [Related]
27. BCL10 as a useful marker for pancreatic acinar cell carcinoma, especially using endoscopic ultrasound cytology specimens.
Hosoda W; Sasaki E; Murakami Y; Yamao K; Shimizu Y; Yatabe Y
Pathol Int; 2013 Mar; 63(3):176-82. PubMed ID: 23530562
[TBL] [Abstract][Full Text] [Related]
28. Intraductal Papillary Mucinous Carcinoma Versus Conventional Pancreatic Ductal Adenocarcinoma: A Comprehensive Review of Clinical-Pathological Features, Outcomes, and Molecular Insights.
Mas L; Lupinacci RM; Cros J; Bachet JB; Coulet F; Svrcek M
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201897
[TBL] [Abstract][Full Text] [Related]
29. Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas.
Amato E; Molin MD; Mafficini A; Yu J; Malleo G; Rusev B; Fassan M; Antonello D; Sadakari Y; Castelli P; Zamboni G; Maitra A; Salvia R; Hruban RH; Bassi C; Capelli P; Lawlor RT; Goggins M; Scarpa A
J Pathol; 2014 Jul; 233(3):217-27. PubMed ID: 24604757
[TBL] [Abstract][Full Text] [Related]
30. Pathways of Progression From Intraductal Papillary Mucinous Neoplasm to Pancreatic Ductal Adenocarcinoma Based on Molecular Features.
Omori Y; Ono Y; Tanino M; Karasaki H; Yamaguchi H; Furukawa T; Enomoto K; Ueda J; Sumi A; Katayama J; Muraki M; Taniue K; Takahashi K; Ambo Y; Shinohara T; Nishihara H; Sasajima J; Maguchi H; Mizukami Y; Okumura T; Tanaka S
Gastroenterology; 2019 Feb; 156(3):647-661.e2. PubMed ID: 30342036
[TBL] [Abstract][Full Text] [Related]
31. Clinicopathological characteristics and molecular analyses of multifocal intraductal papillary mucinous neoplasms of the pancreas.
Matthaei H; Norris AL; Tsiatis AC; Olino K; Hong SM; dal Molin M; Goggins MG; Canto M; Horton KM; Jackson KD; Capelli P; Zamboni G; Bortesi L; Furukawa T; Egawa S; Ishida M; Ottomo S; Unno M; Motoi F; Wolfgang CL; Edil BH; Cameron JL; Eshleman JR; Schulick RD; Maitra A; Hruban RH
Ann Surg; 2012 Feb; 255(2):326-33. PubMed ID: 22167000
[TBL] [Abstract][Full Text] [Related]
32. Serine protease inhibitor Kazal type 1 and epidermal growth factor receptor are expressed in pancreatic tubular adenocarcinoma, intraductal papillary mucinous neoplasm, and pancreatic intraepithelial neoplasia.
Ozaki N; Ohmuraya M; Ida S; Hashimoto D; Ikuta Y; Chikamoto A; Hirota M; Baba H
J Hepatobiliary Pancreat Sci; 2013 Aug; 20(6):620-7. PubMed ID: 23475261
[TBL] [Abstract][Full Text] [Related]
33. GNAS but Not Extended RAS Mutations Spectrum are Associated with a Better Prognosis in Intraductal Pancreatic Mucinous Neoplasms.
Gaujoux S; Parvanescu A; Cesaretti M; Silve C; Bieche I; Rebours V; Lévy P; Sauvanet A; Cros J
Ann Surg Oncol; 2019 Aug; 26(8):2640-2650. PubMed ID: 31025231
[TBL] [Abstract][Full Text] [Related]
34. Invasive ductal adenocarcinoma of the remnant pancreatic body 9 years after resection of an intraductal papillary-mucinous carcinoma of the pancreatic head: a case report and comparison of DNA sequence in K-ras gene mutation.
Komori T; Ishikawa O; Ohigashi H; Yamada T; Sasaki Y; Imaoka S; Nakaizumi A; Uehara H; Tanaka S; Mano Y; Kasugai T
Jpn J Clin Oncol; 2002 Apr; 32(4):146-51. PubMed ID: 12072425
[TBL] [Abstract][Full Text] [Related]
35. GNAS sequencing identifies IPMN-specific mutations in a subgroup of diminutive pancreatic cysts referred to as "incipient IPMNs".
Matthaei H; Wu J; Dal Molin M; Shi C; Perner S; Kristiansen G; Lingohr P; Kalff JC; Wolfgang CL; Kinzler KW; Vogelstein B; Maitra A; Hruban RH
Am J Surg Pathol; 2014 Mar; 38(3):360-3. PubMed ID: 24525507
[TBL] [Abstract][Full Text] [Related]
36. Different subtypes of intraductal papillary mucinous neoplasm in the pancreas have distinct pathways to pancreatic cancer progression.
Mohri D; Asaoka Y; Ijichi H; Miyabayashi K; Kudo Y; Seto M; Ohta M; Tada M; Tanaka Y; Ikenoue T; Tateishi K; Isayama H; Kanai F; Fukushima N; Tada M; Kawabe T; Omata M; Koike K
J Gastroenterol; 2012 Feb; 47(2):203-13. PubMed ID: 22041919
[TBL] [Abstract][Full Text] [Related]
37. Two Large Benign Branch-Duct Gastric-Type Ιntraductal Papillary Mucinous Neoplasms of the Pancreas With Positive GNAS Mutations A Question of When or Using Which Technique to Operate?
Tampakis A; Zettl A; Tampaki EC; Posabella A; von Flüe M; Guenin MO
Pancreas; 2016; 45(5):e16-7. PubMed ID: 27077715
[No Abstract] [Full Text] [Related]
38. Mutational Patterns in Pancreatic Juice of Intraductal Papillary Mucinous Neoplasms and Concomitant Pancreatic Cancer.
Takano S; Fukasawa M; Kadokura M; Shindo H; Takahashi E; Hirose S; Fukasawa Y; Kawakami S; Hayakawa H; Maekawa S; Mochizuki K; Kawaida H; Kono H; Itakura J; Sato T; Ichikawa D; Enomoto N
Pancreas; 2019 Sep; 48(8):1032-1040. PubMed ID: 31404021
[TBL] [Abstract][Full Text] [Related]
39. Clinical role of Notch signaling pathway in intraductal papillary mucinous neoplasm of the pancreas.
Ikemoto T; Sugimoto K; Shimada M; Utsunomiya T; Morine Y; Imura S; Arakawa Y; Kanamoto M; Iwahashi S; Saito Y; Yamada S
J Gastroenterol Hepatol; 2015 Jan; 30(1):217-22. PubMed ID: 25041344
[TBL] [Abstract][Full Text] [Related]
40. Loss of Pten and Activation of Kras Synergistically Induce Formation of Intraductal Papillary Mucinous Neoplasia From Pancreatic Ductal Cells in Mice.
Kopp JL; Dubois CL; Schaeffer DF; Samani A; Taghizadeh F; Cowan RW; Rhim AD; Stiles BL; Valasek M; Sander M
Gastroenterology; 2018 Apr; 154(5):1509-1523.e5. PubMed ID: 29273451
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
